EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Comparable transplant outcomes with a decitabine-based reduced-toxicity regimen versus modified BUCY in older or frail MDS patients: A retrospective analysis of real-world practice

Yanling Ren, Wei Lang, Yu Xu, Chen Mei, Xianbo Huang, Shasha Wang, Jiejing Qian, Hongyan Tong

Therapeutic Advances in Hematology · 2026-11 · 17

DOI: 10.1177/20406207261508776 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Therapeutic Advances in Hematology, online erschienen am 17.11.2026. Verfasst von Yanling Ren und 7 weiteren Autor:innen. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the only curative option for myelodysplastic syndromes (MDS), yet conventional myeloablative conditioning is highly toxic in elderly or frail patients.

Objectives

To compare a decitabine-based reduced-toxicity conditioning (RTC) regimen with modified BUCY in higher-risk MDS patients undergoing allo-HSCT in a real-world setting.

Design

Single-center retrospective cohort study.

Methods

We retrospectively analyzed 82 consecutive MDS patients undergoing first allo-HSCT between September 2022 and June 2025. Thirty-six patients received decitabine-based RTC (decitabine 20 mg/m 2 /day ×3 days with reduced-dose busulfan and fludarabine), while 46 received modified BUCY. End points were overall survival (OS), relapse-free survival (RFS), cumulative incidence of relapse (CIR), and non-relapse mortality (NRM).

Results

The RTC group had higher baseline risks, including older age (median 57 vs. 53 years, P

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Ren, Y., Lang, W., Xu, Y., Mei, C., Huang, X., Wang, S., Qian, J., & Tong, H. (2026). Comparable transplant outcomes with a decitabine-based reduced-toxicity regimen versus modified BUCY in older or frail MDS patients: A retrospective analysis of real-world practice. Therapeutic Advances in Hematology, 17. https://doi.org/10.1177/20406207261508776

Vancouver

Ren Y, Lang W, Xu Y, Mei C, Huang X, Wang S, et al. Comparable transplant outcomes with a decitabine-based reduced-toxicity regimen versus modified BUCY in older or frail MDS patients: A retrospective analysis of real-world practice. Therapeutic Advances in Hematology. 2026;17. doi:10.1177/20406207261508776

BibTeX
@article{Ren2026,
  author = {Ren, Yanling and Lang, Wei and Xu, Yu and Mei, Chen and Huang, Xianbo and Wang, Shasha and Qian, Jiejing and Tong, Hongyan},
  title = {Comparable transplant outcomes with a decitabine-based reduced-toxicity regimen versus modified BUCY in older or frail MDS patients: A retrospective analysis of real-world practice},
  journal = {Therapeutic Advances in Hematology},
  year = {2026},
  volume = {17},
  doi = {10.1177/20406207261508776}
}
Kostenlos starten →